HighMark Wealth Management’s West Pharmaceutical WST Stock Holding History

HighMark Wealth Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$151K	Hold	420	–	–	0.05%	101
2026 Q1	$105K	Hold	420	–	–	0.04%	109
2025 Q4	$116K	Hold	420	–	–	0.05%	107
2025 Q3	$110K	Hold	420	–	–	0.05%	110
2025 Q2	$91.9K	Hold	420	–	–	0.04%	119
2025 Q1	$94K	Hold	420	–	–	0.06%	93
2024 Q4	$138K	Hold	420	–	–	0.08%	73
2024 Q3	$126K	Hold	420	–	–	0.07%	90
2024 Q2	$138K	Hold	420	–	–	0.08%	78
2024 Q1	$166K	Hold	420	–	–	0.1%	72
2023 Q4	$148K	Hold	420	–	–	0.11%	70
2023 Q3	$158K	Hold	420	–	–	0.13%	55
2023 Q2	$161K	Sell	420 -85	-17%	-$30.4K	0.12%	58
2023 Q1	$175K	Buy	+505	New	+$148K	0.14%	59
2020 Q3	–	Sell	-18	Closed	-$4K	–	481
2020 Q2	$4K	Buy	+18	New	+$3.54K	﹤0.01%	346

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

HighMark Wealth Management's WST Position: Q2 2026 in Review

HighMark Wealth Management held its West Pharmaceutical (WST) position steady in Q2 2026 at 420 shares worth $151K. The position accounts for 0.05% of the portfolio, ranked #101.

HighMark Wealth Management first reported a position in WST in Q2 2020 and has held it in 15 quarters since. The position peaked at $175K in Q1 2023. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

HighMark Wealth Management held 420 shares of West Pharmaceutical worth $151K as of Q2 2026.
HighMark Wealth Management left its West Pharmaceutical share count unchanged in Q2 2026.
West Pharmaceutical made up 0.05% of HighMark Wealth Management's portfolio in Q2 2026, its #101 holding.
HighMark Wealth Management first reported a position in West Pharmaceutical in Q2 2020 and has held it in 15 quarters since.
HighMark Wealth Management's West Pharmaceutical position peaked at $175K in Q1 2023.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.